Boone Capital Management
Latest statistics and disclosures from Boone Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are UNM, ENOV, AMGN, CVS, GMED, and represent 37.69% of Boone Capital Management's stock portfolio.
- Added to shares of these 10 stocks: CVS (+$29M), AMPH (+$25M), VTRS (+$21M), BERY (+$16M), XENE (+$12M), BIO (+$12M), OFIX (+$6.7M), MLAB (+$6.7M), GMED (+$5.4M), BBIO (+$5.1M).
- Started 9 new stock positions in MLAB, AMPH, BIO, CVS, PNTG, VTRS, BERY, XENE, OFIX.
- Reduced shares in these 5 stocks: , MOH (-$16M), CI (-$12M), DHR, IDYA.
- Sold out of its position in BIIB.
- Boone Capital Management was a net buyer of stock by $97M.
- Boone Capital Management has $428M in assets under management (AUM), dropping by 35.16%.
- Central Index Key (CIK): 0001882053
Tip: Access up to 7 years of quarterly data
Positions held by Boone Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Boone Capital Management
Boone Capital Management holds 21 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Unum (UNM) | 10.2 | $44M | +10% | 962k | 45.22 |
|
| Colfax Corp (ENOV) | 7.4 | $32M | +11% | 563k | 56.02 |
|
| Amgen (AMGN) | 6.8 | $29M | +3% | 102k | 288.02 |
|
| CVS Caremark Corporation (CVS) | 6.8 | $29M | NEW | 367k | 78.96 |
|
| Globus Med Cl A (GMED) | 6.6 | $28M | +23% | 530k | 53.29 |
|
| Cigna Corp (CI) | 6.3 | $27M | -31% | 90k | 299.45 |
|
| Danaher Corporation (DHR) | 5.9 | $25M | -15% | 109k | 231.34 |
|
| Amphastar Pharmaceuticals (AMPH) | 5.8 | $25M | NEW | 400k | 61.85 |
|
| Molina Healthcare (MOH) | 5.8 | $25M | -39% | 68k | 361.31 |
|
| Baxter International (BAX) | 4.9 | $21M | +16% | 549k | 38.66 |
|
| Viatris (VTRS) | 4.8 | $21M | NEW | 1.9M | 10.83 |
|
| Ideaya Biosciences (IDYA) | 4.4 | $19M | -6% | 532k | 35.58 |
|
| Bridgebio Pharma (BBIO) | 4.2 | $18M | +40% | 441k | 40.37 |
|
| Berry Plastics (BERY) | 3.6 | $16M | NEW | 232k | 67.39 |
|
| Quanterix Ord (QTRX) | 3.6 | $16M | 569k | 27.34 |
|
|
| Mirum Pharmaceuticals (MIRM) | 3.4 | $15M | +25% | 490k | 29.52 |
|
| Xenon Pharmaceuticals (XENE) | 2.7 | $12M | NEW | 255k | 46.06 |
|
| Bio Rad Labs Cl A (BIO) | 2.7 | $12M | NEW | 36k | 322.89 |
|
| Orthofix Medical (OFIX) | 1.6 | $6.7M | NEW | 500k | 13.48 |
|
| Mesa Laboratories (MLAB) | 1.6 | $6.7M | NEW | 64k | 104.77 |
|
| Pennant Group (PNTG) | 1.1 | $4.6M | NEW | 330k | 13.92 |
|
Past Filings by Boone Capital Management
SEC 13F filings are viewable for Boone Capital Management going back to 2022
- Boone Capital Management 2023 Q4 filed Feb. 14, 2024
- Boone Capital Management 2023 Q3 filed Nov. 14, 2023
- Boone Capital Management 2023 Q2 filed Aug. 14, 2023
- Boone Capital Management 2023 Q1 filed May 15, 2023
- Boone Capital Management 2022 Q4 filed Feb. 14, 2023